文献速递外周动脉疾病

新一代球囊扩张式覆膜支架治疗髂动脉闭塞性疾病的 pivotal 研究

Pivotal Study of a Next-Generation Balloon-Expandable Stent-Graft for Treatment of Iliac Occlusive Disease.
PubMed 文献 · J Endovasc Ther · 2017-07-12

该前瞻性、多中心、单臂研究评估 VBX 覆膜支架治疗髂动脉原发或再狭窄病变的安全性与有效性,纳入 134 例患者共 213 处病变。9 个月时主要复合终点事件发生率为 2.3%(3 例 TLR),无器械相关严重不良事件,显示良好的短期安全性和有效性。

要点

  • 9 个月主要复合终点事件率为 2.3%,均为靶病变血运重建。
  • 技术成功率 100%,无器械相关严重不良事件。
  • 42.5% 患者接受主动脉分叉处对吻支架。

核心结论

  • 新一代球囊扩张式覆膜支架在反映常见临床实践的患者中治疗髂动脉闭塞性疾病,9 个月安全性和有效性显著。

研究设计与样本

  • 前瞻性、多中心、单臂安全性和有效性研究,在美国 26 个中心和 1 个新西兰中心开展,纳入 134 例患者(平均年龄 66±9.5 岁;79 例男性)共 213 处髂动脉病变。

主要发现

  • 共植入 234 枚器械,技术成功率 100%;57 例(42.5%)患者在主动脉分叉处接受对吻支架。
  • 9 个月时,132 例患者中 3 例(2.3%)发生主要不良事件(3 例 TLR),与主要终点相关。
  • 9 个月时无器械相关严重不良事件或非预期器械不良反应。

关键数值与推荐

  • 主要终点为 30 天内器械或手术相关死亡、30 天内心肌梗死、9 个月内靶病变血运重建(TLR)以及 9 个月内治疗侧足趾以上截肢的复合终点。
  • 101 例(75.4%)患者为 Rutherford 3 级缺血,43 例(32.1%)为 TASC II C/D 级病变。

临床怎么用

  • 对于髂动脉原发或再狭窄病变,尤其是复杂病变(TASC II C/D),可考虑使用该覆膜支架,短期结果良好。

局限性

  • 单臂研究设计,无对照组,随访时间仅 9 个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of a next-generation balloon-expandable stent-graft for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or external iliac arteries. METHODS: A prospective, multicenter, single-arm safety and efficacy study ( ClinicalTrials.gov identifier: NCT02080871) of the VBX Stent Graft for treatment of de novo or restenotic lesions in the iliac arteries was conducted under an Investigational Device Exemption at 26 US sites and 1 New Zealand center. The study eligibility criteria were established with the aim of enrolling more "real-world" patients compared with previous iliac stent studies supporting Food and Drug Administration approval. The study enrolled 134 patients (mean age 66±9.5 years; 79 men) with 213 iliac lesions. Three-quarters of the population (101, 75.4%) had Rutherford category 3 ischemia, and 43 (32.1%) patients presented with TASC II C/D lesions. The primary endpoint was a composite of device- or procedure-related death within 30 days, myocardial infarction within 30 days, target lesion revascularization (TLR) within 9 months, and amputation above the metatarsals in the treated leg within 9 months. RESULTS: In all, 234 devices were implanted in 213 lesions with 100% technical success; 57 (42.5%) patients received kissing stents at the aortic bifurcation. No devices exhibited a discernable change in length after final deployment as determined by independent core laboratory quantitative angiographic analysis. At 9 months, 3 (2.3%) of 132 patients (1 lost to follow-up, 1 unrelated death) experienced a major adverse event (3 TLRs) related to the primary endpoint. At 9 months, there were no device-related serious adverse events or unanticipated adverse device effects. CONCLUSION: The next-generation balloon-expandable stent-graft demonstrated notable 9-month safety and efficacy in treating iliac occlusive disease in patients reflecting common clinical practice.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bismuth J, Gray BH, Holden A, et al. Pivotal Study of a Next-Generation Balloon-Expandable Stent-Graft for Treatment of Iliac Occlusive Disease. J Endovasc Ther. 2017. PMID: 28697693. doi:10.1177/1526602817720463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。